Multimodality nanotracers for cardiovascular applications

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue SUPPL. 2, 2008, Pages

  Mulder, Willem J M ^a   Cormode, David P ^a   Hak, Sjoerd ^d   Lobatto, Mark E ^b   Silvera, Stephane ^c   Fayad, Zahi A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Cochin Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BISMUTH; COLLOIDAL GOLD; CORTICOSTEROID; CYTOSTATIC AGENT; DENDRIMER; DEXTRAN; DNA; DOXORUBICIN; GADOLINIUM PENTETATE; GADOTERIC ACID; GOLD; IRON OXIDE; LIPOPROTEIN; LIPOSOME; MACROGOL; MANGANESE; MESSENGER RNA; MOLECULAR MARKER; NANOPARTICLE; POLYSACCHARIDE; QUANTUM DOT; RNA; SILICON DIOXIDE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRACER; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CARDIOVASCULAR DISEASE; DRUG DELIVERY SYSTEM; EARLY DIAGNOSIS; ECHOGRAPHY; FLUORESCENCE MICROSCOPY; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; LOW LEVEL LASER THERAPY; MACROPHAGE; MAGNETOTHERAPY; MICELLE; MICROEMULSION; MOLECULAR PROBE; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RNA INTERFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY IMAGING;

CARDIOVASCULAR DISEASES; DIAGNOSTIC IMAGING; HUMANS; NANOPARTICLES;

EID: 48349090348     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1242     Document Type: Article

References (72)

1. Choudhury RP et al. (2004) Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 3: 913-925
2. Jaffer FA et al. (2006) Molecular and cellular imaging of atherosclerosis: Emerging applications. J Am Coll Cardiol 47 1328-1338
3. Weissleder R and Mahmood U (2001) Molecular imaging. Radiology 219: 316-333
4. Mulder WJ et al. (2006) Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 19: 142-164
5. Mulder WJ et al. (2007) Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine 2: 307-324
6. Frullano L and Meade TJ (2007) Multimodal MRI contrast agents. J Biol Inorg Chem 12: 939-949
7. Mulder WJ et al. (2005) MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 19: 2008-2010
8. Josephson L et al. (2002) Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem 13: 554-560
9. Moghimi SM et al. (2005) Nanomedicine: Current status and future prospects. FASEB J 19: 311-330
10. Midgley PA et al. (2007) Nanotomography in the chemical, biological and materials sciences. Chem Soc Rev 36: 1477-1494
11. Wickline SA et al. (2006) Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 26: 435-441
12. Bangham AD et al. (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13: 238-252
13. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160
14. Aragnol D and Leserman LD (1986) Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci USA 86: 2699-2703
15. Allen TM and Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: Effect of dose. Biochim Biophys Acta 1068: 133-141
16. Allen TM et al. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066: 29-36
17. Soo Choi H et al. (2007) Renal clearance of quantum dots. Nat Biotechnol 25: 1165-1170
18. Liu Y et al. (2007) Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 120: 2527-2537
19. Yih TC and Wei C (2005) Nanomedicine in cancer treatment. Nanomedicine 1: 191-192
20. Sofou S (2007) Surface-active liposomes for targeted cancer therapy. Nanomedicine 2: 711-724
21. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2: 750-763
22. Bulte JW and Kraitchman DL (2004) Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 17: 484-499
23. Michalet X et al. (2005) Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307: 538-544
24. Lanza GM et al. (2006) Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine 1: 321-329
25. Romberg B et al. (2008) Sheddable coatings for long-circulating nanoparticles. Pharm Res 25: 55-71
26. Rutten A and Prokop M (2007) Contrast agents in X-ray computed tomography and its applications in oncology. Anticancer Agents Med Chem 7: 307-316
27. Kim D et al. (2007) Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J Am Chem Soc 129: 7661-7665
28. Rabin O et al. (2006) An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater 5: 118-122
29. Strijkers GJ et al. (2007) MRI contrast agents: Current status and future perspectives. Anticancer Agents Med Chem 7: 291-305
30. Morawski AM et al. (2005) Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol 16: 89-92
31. Roby A et al. (2007) Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumortargeted immunomicelles. Cancer Biol Ther 6: 1136-1142
32. Gulati M et al. (1998) Lipophilic drug derivatives in liposomes. Int J Pharm 165: 129-168
33. Lanza GM et al. (2002) Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: Implications for rational therapy of restenosis. Circulation 106: 2842-2847
34. Liu Y et al. (2007) Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 120: 2527-2537
35. O'Neal DP et al. (2004) Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett 209: 171-176
36. Hood JD et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404-2407
37. Mastrobattista E et al. (2002) Targeted liposomes for delivery of protein-based drugs into the cytoplasm of tumor cells. J Liposome Res 12: 57-65
38. Mulder WJ et al. (2004) A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem 15: 799-806
39. Kao CY et al. (2003) Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol 10: 475-483
40. Hamilton A et al. (2002) Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: Studies in a new experimental model. Circulation 105: 2772-2778
41. Marik J et al. (2007) Long-circulating liposomes radiolabeled with [18F]fluorodipalmitin ([18F]FDP). Nucl Med Biol 34: 165-171
42. Harrington KJ et al. (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7: 243-254
43. Torchilin VP (2007) Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res 24: 1-16
44. Torchilin VP (2004) Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 61: 2549-2559
45. Fortina P et al. (2007) Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends Biotechnol 25:145-152
46. Vogl TJ et al. (1996) Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Invest Radiol 31: 696-708
47. Mack MG et al. (2002) Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 222: 239-244
48. Tang T et al. (2006) Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke 37: 2266-2270
49. de Vries IJ et al. (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23: 1407-1413
50. McCarthy JR et al. (2007) Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine 2: 153-167
51. Kircher MF et al. (2003) A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 63: 8122-8125
52. Jaffer FA et al. (2006) Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol Imaging 5: 85-92
53. Nahrendorf M et al. (2006) Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114: 1504-1511
54. Mulder WJ et al. (2006) Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett 6: 1-6
55. Frias JC et al. (2004) Recombinant HDL-like nanoparticles: A specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 126: 16316-16317
56. Zheng G et al. (2005) Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA 102 17757-17762
57. Frias JC et al. (2006) Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett 6: 2220-2224
58. Svenson S and Tomalia DA (2005) Dendrimers in biomedical applications_reflections on the field. Adv Drug Deliv Rev 57 2106-2129
59. Anderson EA et al. (2006) Viral nanoparticles donning a paramagnetic coat: Conjugation of MRI contrast agents to the MS2 capsid. Nano Lett 6: 1160-1164
60. Bridot JL et al. (2007) Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc 129: 5076-5084
61. Rieter WJ et al. (2007) Hybrid silica nanoparticles for multimodal imaging. Angew Chem Int Ed Engl 46: 3680-3682
62. Sitharaman B et al. (2005) Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun (Camb) 3915-3917
63. Ruehm SG et al. (2001) Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103: 415-422
64. Kooi ME et al. (2003) Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107 2453-2458
65. Amirbekian V et al. (2007) Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci USA 104: 961-966
66. Hyafil F et al. (2007) Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 13: 636-641
67. Winter PM et al. (2006) Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26: 2103-2109
68. Medarova Z et al. (2007) In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 13: 372-377
69. Pissuwan D et al. (2006) Therapeutic possibilities of plasmonically heated gold nanoparticles. Trends Biotechnol 24 62-67
70. Samia AC et al. (2003) Semiconductor quantum dots for photodynamic therapy. J Am Chem Soc 125: 15736-15737
71. Roy I et al. (2005) Optical tracking of organically modified silica nanoparticles as DNA carriers: A nonviral, nanomedicine approach for gene delivery. Proc Natl Acad Sci USA 102: 279-284
72. Ogawara K et al. (2006) Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene. Arthritis Res Ther 8: R32